Has Yolanda Pena, MD received payments from drug or device companies?

Yes. Drug and device makers reported $853 in general payments to Yolanda Pena, MD across 37 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Yolanda Pena, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Yolanda Pena, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Yolanda Pena, MD

Neurology · Avon, CTNPI 1659348365

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $399 and has fallen 96.3% since, to $15 in 2024. That places this record below the midpoint for neurology clinicians in CT, where the typical reported total is $893.

$853in general payments, 2019–2025

Across 37 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Lilly USA, LLC$195
UCB, Inc.$160
Greenwich Biosciences, Inc.$132
Livanova USA, Inc.$111
SK Life Science, Inc.$96
Amgen$58
plus $101 from 5 others

$4,840in research payments, 2019–2025

Across 1 payment — averaging $4840.20 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Eisai Inc.$5K

What the payments were for

Speaking & faculty fees$172%
Food & beverage$83698%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Lilly USA, LLC	6	$195
UCB, Inc.	9	$160
Greenwich Biosciences, Inc.	1	$132
Livanova USA, Inc.	6	$111
SK Life Science, Inc.	4	$96
Amgen	4	$58
AbbVie(2 entities)	2	$32
Teva Pharmaceuticals USA, Inc.	2	$26
Acorda Therapeutics, Inc	1	$17
Novartis	1	$14
Sanofi	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Epidiolex$132

How this compares

$853 in reported general payments places this provider in the 45th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$11,541

Medicare patients

Services billed

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
KeppraLevetiracetam	14	$22,971
Lacosamide	118	$8,724
Levetiracetam	160	$3,978
Carbamazepine ErCarbamazepine	19	$3,919
Oxcarbazepine	23	$1,225
Divalproex Sodium	13	$1,166
Primidone	65	$1,012
Armodafinil	12	$800
Gabapentin	37	$773
Carbamazepine	26	$719
Carbidopa-LevodopaCarbidopa/Levodopa	27	$484
Baclofen	12	$218
Fluoxetine Hcl	19	$198
Trihexyphenidyl Hcl	13	$76
Trazodone Hcl	16	$66

Paid to pharmacies, not to this prescriber.

Other neurology in Avon

Peter McAllisterFairfield$2.3M
Stewart TepperStamford$1.2M
Sharon StollNew Haven$822K
Mary BaileyNew Haven$630K
Wanda Castro-BorreroFarmington$553K
Derek SmithNorwich$469K
Deena KuruvillaWestport$440K
Duarte MachadoCheshire$426K
Tanya BilchikEast Hartford$361K
Peter GottschalkFairfield$318K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →